We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
Read MoreHide Full Article
Key Takeaways
FMS launches its FDA-cleared multiFiltratePRO System in the United States to treat acute kidney injury.
The system integrates citrate and calcium pumps to simplify treatment delivery and automate ICU procedures.
Fresenius Medical Care plans a phased U.S. rollout, targeting growth in hospital-based acute kidney care.
Fresenius Medical Care AG & Co. (FMS - Free Report) recently announced the U.S. launch of its multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). The launch follows the recent FDA clearance of the system and approval of Cienby (sodium citrate solution) and Calrezdy (calcium chloride solution) in October. The integrated continuous kidney replacement therapy (CKRT) system is designed to simplify treatment delivery in intensive care units by automating key aspects of regional citrate anticoagulation (RCA).
Per management, Fresenius Medical Care has remained focused on bringing innovative kidney care solutions to patients worldwide and expanding their availability to new markets. The multiFiltratePRO system broadens treatment options for U.S. critical care teams and reinforces FMS' leadership on advancing kidney care technology.
FMS Stock Trend Following the News
FMS stock has gained 3.1% since the announcement on Wednesday. Year to date, the stock has fallen 6.7% compared with the industry’s 1.5% decline. However, the S&P 500 has risen 11.2% during the same timeframe.
The U.S. launch of multiFiltratePRO could support FMS' growth by expanding its presence in the hospital-based acute kidney care market. The system's integrated design may appeal to hospitals seeking to simplify complex ICU procedures and improve treatment workflow management. The launch also creates opportunities to strengthen relationships with critical care providers and expand sales of associated products, including the dedicated solutions. Adoption across U.S. hospitals could broaden FMS' revenue opportunities in a market where specialized kidney replacement therapies are essential.
FMS currently has a market capitalization of $11.58 billion.
Image Source: Zacks Investment Research
More on the News
The multiFiltratePRO System is designed to deliver CKRT to adults and pediatric patients weighing at least 40 kilograms who require treatment for AKI. The system integrates citrate and calcium pumps, eliminating the need for separate external infusion pumps. Through the Ci-Ca protocol, infusion rates automatically adjust to changes in blood and effluent flow, helping clinicians maintain protocol-defined ratios during treatment.
Fresenius Medical Care also received FDA approval for Cienby and Calrezdy. Cienby is indicated for RCA during continuous venovenous hemodialysis (CVVHD) or continuous venovenous hemodiafiltration (CVVHDF), while Calrezdy provides calcium substitution during these procedures. Both products are approved for eligible adult and pediatric patients weighing at least 40 kilograms.
A multicenter randomized controlled trial found that citrate anticoagulation extended filter lifespan compared with systemic heparin in critically ill patients receiving CKRT, although it could not establish definitive conclusions about mortality.
The launch follows FMS' introduction of the 5008X CAREsystem in the United States, bringing hemodiafiltration to the market. The multiFiltratePRO System will be showcased at ASN Kidney Week 2026 in Denver, where healthcare professionals can learn about its capabilities.
FMS plans to begin the U.S. launch with a controlled rollout before moving quickly to full availability. The product's commercial contribution will depend on adoption by hospitals and critical care teams as the rollout progresses.
Industry Prospects Favoring the Market
According to Fortune Business Insights, the global continuous renal replacement therapy (CRRT) market is estimated to be valued at $1.34 billion in 2026 and is expected to witness a CAGR of 8.2% through 2034.
Factors such as rising ICU admissions, the growing prevalence of AKI and sepsis and technological innovations in kidney care systems are driving market growth.
Other News
Fresenius Medical Care recently refined its China commercial strategy to focus on areas offering stronger long-term growth potential and strengthen its position in the country’s dialysis market. The company plans to prioritize advanced in-center dialysis and critical-care technologies while streamlining parts of its existing portfolio and adopting a more focused go-to-market approach.
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently sporting a Zacks Rank #1, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Bigstock
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI
Key Takeaways
Fresenius Medical Care AG & Co. (FMS - Free Report) recently announced the U.S. launch of its multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). The launch follows the recent FDA clearance of the system and approval of Cienby (sodium citrate solution) and Calrezdy (calcium chloride solution) in October. The integrated continuous kidney replacement therapy (CKRT) system is designed to simplify treatment delivery in intensive care units by automating key aspects of regional citrate anticoagulation (RCA).
Per management, Fresenius Medical Care has remained focused on bringing innovative kidney care solutions to patients worldwide and expanding their availability to new markets. The multiFiltratePRO system broadens treatment options for U.S. critical care teams and reinforces FMS' leadership on advancing kidney care technology.
FMS Stock Trend Following the News
FMS stock has gained 3.1% since the announcement on Wednesday. Year to date, the stock has fallen 6.7% compared with the industry’s 1.5% decline. However, the S&P 500 has risen 11.2% during the same timeframe.
The U.S. launch of multiFiltratePRO could support FMS' growth by expanding its presence in the hospital-based acute kidney care market. The system's integrated design may appeal to hospitals seeking to simplify complex ICU procedures and improve treatment workflow management. The launch also creates opportunities to strengthen relationships with critical care providers and expand sales of associated products, including the dedicated solutions. Adoption across U.S. hospitals could broaden FMS' revenue opportunities in a market where specialized kidney replacement therapies are essential.
FMS currently has a market capitalization of $11.58 billion.
Image Source: Zacks Investment Research
More on the News
The multiFiltratePRO System is designed to deliver CKRT to adults and pediatric patients weighing at least 40 kilograms who require treatment for AKI. The system integrates citrate and calcium pumps, eliminating the need for separate external infusion pumps. Through the Ci-Ca protocol, infusion rates automatically adjust to changes in blood and effluent flow, helping clinicians maintain protocol-defined ratios during treatment.
Fresenius Medical Care also received FDA approval for Cienby and Calrezdy. Cienby is indicated for RCA during continuous venovenous hemodialysis (CVVHD) or continuous venovenous hemodiafiltration (CVVHDF), while Calrezdy provides calcium substitution during these procedures. Both products are approved for eligible adult and pediatric patients weighing at least 40 kilograms.
A multicenter randomized controlled trial found that citrate anticoagulation extended filter lifespan compared with systemic heparin in critically ill patients receiving CKRT, although it could not establish definitive conclusions about mortality.
The launch follows FMS' introduction of the 5008X CAREsystem in the United States, bringing hemodiafiltration to the market. The multiFiltratePRO System will be showcased at ASN Kidney Week 2026 in Denver, where healthcare professionals can learn about its capabilities.
FMS plans to begin the U.S. launch with a controlled rollout before moving quickly to full availability. The product's commercial contribution will depend on adoption by hospitals and critical care teams as the rollout progresses.
Industry Prospects Favoring the Market
According to Fortune Business Insights, the global continuous renal replacement therapy (CRRT) market is estimated to be valued at $1.34 billion in 2026 and is expected to witness a CAGR of 8.2% through 2034.
Factors such as rising ICU admissions, the growing prevalence of AKI and sepsis and technological innovations in kidney care systems are driving market growth.
Other News
Fresenius Medical Care recently refined its China commercial strategy to focus on areas offering stronger long-term growth potential and strengthen its position in the country’s dialysis market. The company plans to prioritize advanced in-center dialysis and critical-care technologies while streamlining parts of its existing portfolio and adopting a more focused go-to-market approach.
Fresenius Medical Care AG & Co. KGaA Price
Fresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote
FMS’ Zacks Rank & Key Picks
Currently, Fresenius Medical Care carries a Zacks Rank #4 (Sell).
Some top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently sporting a Zacks Rank #1, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.